MA-IBASIS
18.5.2021 07:02:13 CEST | Business Wire | Press release
iBASIS , the leading provider of communications solutions for operators and digital players worldwide, today announced the launch of iBASIS Carrier Voice for Teamwork , enabling carriers such as China Telecom Europe (CTE), a leading provider to European multinationals, to serve Enterprise customers with much needed cloud-based PBX functionality for their collaboration platforms.
With the massive shift toward Microsoft Teams triggered by COVID-19, carriers have an immediate opportunity to seize new Enterprise revenues by delivering a proven solution to bring voice to Microsoft Teams. iBASIS Carrier Voice for Teamwork™ provides global service availability, from and to the cloud via 2-way PSTN numbers, enabling native voice service in 60+ markets for global termination to help carriers respond to their local Enterprise demand. Carriers have the option to keep their own numbers to avoid porting or leverage iBASIS for local numbers.
The solution is built on iBASIS’ established wholesale leadership to drive voice capabilities for Microsoft Teams and deliver proven performance ensuring that carriers like CTE gain extremely quick time-to-market with its pay-as-you-go model, flexible pricing plans, easy configuration, and self-service portal.
”iBASIS Carrier Voice for Teamwork provides China Telecom Europe (CTE) with voice for Microsoft Teams to respond to and support their Enterprise customers with more effective collaboration across the globe ,” says Edwin van Ierland, Chief Commercial Officer and Chief Operating Officer at iBASIS. “Leveraging our reach, scale, independence, and leading technology partnerships, CTE was able to rapidly roll out easy-to-deploy capabilities to meet fast-moving market conditions. ”
“Our value proposition at China Telecom Europe (CTE) is differentiated by our holistic ICT approach, ” adds Nathan Li, Deputy Director, Voice & Messaging, China Telecom Europe. “The iBASIS Carrier Voice for Teamwork™ provides us with a proven, highly flexible solution with a customer-friendly commercial structure that helps us to quickly adapt to new opportunities for business growth. We trust iBASIS to continue delivering on quality, opportunity, and partnership. ”
iBASIS plans to broaden Carrier Voice for Teamwork to other tools, like Slack, Zoom, and WebEx. The solution is part of iBASIS’ larger Carrier Cloud Communications portfolio, which includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS continues to enable carriers with opportunities to regain control and outperform throughout the large-scale transformations of their Enterprise customers.
Please visit us online for more information about iBASIS Carrier Voice for Teamwork .
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global , iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, and Top 3 LTE IPX vendor with 700+ LTE destinations. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com .
ABOUT CHINA TELECOM (EUROPE) LTD.
China Telecom (Europe) Ltd . (CTE) provides integrated telecommunications and technology services as local, regional, and global solutions for Chinese, Asian, and European multinational corporations. CTE’s unrivaled knowledge of the Chinese market and regional offices across Europe make CTE an ideal partner for European and Asian businesses looking to work in China and Asia. Please visit us online for more information at chinatelecomeurope.com .
iBASIS® and other marks as indicated are the trademarks or registered trademarks of iBASIS, Inc. or other companies in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005948/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom